SCHEMBL3152897

SCHEMBL3152897

O=C(NCC(O)CNc1ccc(N2CCCC2)c(Cl)c1)C1=CC(Cl)=CCC1=S

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.43
RECQL P46063 1/20 0.43
NPSR1 Q6W5P4 4/20 0.42
MAPT P10636 11/20 0.41
SMN1; SMN2 Q16637 10/20 0.41
ALDH1A1 P00352 10/20 0.40
RAB9A P51151 8/20 0.40
MEN1 O00255 8/20 0.40
KMT2A Q03164 8/20 0.40
NPC1 O15118 7/20 0.40
LMNA P02545 5/20 0.40
MAPK1 P28482 3/20 0.40
NFKB1 P19838 2/20 0.40
NFKB2 Q00653 2/20 0.40
RELA Q04206 2/20 0.40
TP53 P04637 2/20 0.40
CASP1 P29466 1/20 0.40
GAA P10253 1/20 0.40
THRB P10828 1/20 0.40
HTT P42858 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3140868 0.90 TAAR1 (0.39) KDM4ERECQLMAPTSMN1; SMN2TP53
SCHEMBL3155715 0.88 RAB9A (0.36) KDM4ERECQLNPSR1MAPTSMN1; SMN2
SCHEMBL3156588 0.84 F10 (0.44)
SCHEMBL3148099 0.83 GAA (0.39) KDM4EMAPTSMN1; SMN2ALDH1A1RAB9A
SCHEMBL3143074 0.83 ALDH1A1 (0.41) KDM4EMAPTSMN1; SMN2ALDH1A1RAB9A
SCHEMBL3151531 0.82 LMNA (0.42) KDM4EMAPTSMN1; SMN2ALDH1A1RAB9A
SCHEMBL3156839 0.82 GRM1 (0.33) MAPTALDH1A1HTT
SCHEMBL3150497 0.80 GRM4 (0.33)
SCHEMBL3160025 0.80 MAPT (0.36) KDM4EMAPTSMN1; SMN2ALDH1A1MEN1
SCHEMBL3151199 0.80 MAPT (0.32) KDM4EMAPTSMN1; SMN2LMNAMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1526132-B1 Substituted oxazolidinone derivatives and their use as factor xa inhibitors BAYER IP GMBH (DE) 2014-03-12 EP disclosed
EP-1411932-B1 SUBSTITUTED OXAZOLIDINONES FOR COMBINATIONAL THERAPY BAYER SCHERING PHARMA AG (DE) 2010-02-10 EP disclosed
EP-2099453-A2 COMBINATION THERAPY OF SUBSTITUTED OXAZOLIDINONES Bayer Schering Pharma Aktiengesellschaft (DE) 2009-09-16 EP disclosed
EP-1937271-A1 MICROANGIOPATHY TREATMENT AND PREVENTION Bayer HealthCare AG (DE) 2008-07-02 EP disclosed
WO-2008052671-A2 COMBINATION THERAPY OF SUBSTITUTED OXAZOLIDINONES BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2008-05-08 WO disclosed
WO-2007042146-A1 MICROANGIOPATHY TREATMENT AND PREVENTION BAYER HEALTHCARE AG (DE) 2007-04-19 WO disclosed
EP-1526132-A2 Substituted oxazolidinone derivatives and their use as factor xa inhibitors Bayer HealthCare AG (DE) 2005-04-27 EP disclosed
EP-1261606-B1 SUBSTITUTED OXAZOLIDINONES AND THEIR USE IN THE FIELD OF BLOOD COAGULATION BAYER HEALTHCARE AG (DE) 2005-02-23 EP disclosed
EP-1411932-A1 SUBSTITUTED OXAZOLIDINONES FOR COMBINATIONAL THERAPY Bayer HealthCare AG (DE) 2004-04-28 EP disclosed
WO-2003000256-A9 SUBSTITUTED OXAZOLIDINONES FOR COMBINATIONAL THERAPY BAYER AG (DE) 2003-02-06 WO disclosed
WO-2003000256-A1 SUBSTITUTED OXAZOLIDINONES FOR COMBINATIONAL THERAPY BAYER HEALTHCARE AG (DE) 2003-01-03 WO disclosed
WO-2001047919-A9 SUBSTITUTED OXAZOLIDINONES AND THEIR USE IN THE FIELD OF BLOOD COAGULATION BAYER AG (DE) 2002-12-19 WO disclosed
EP-1261606-A1 SUBSTITUTED OXAZOLIDINONES AND THEIR USE IN THE FIELD OF BLOOD COAGULATION Bayer Aktiengesellschaft (DE) 2002-12-04 EP disclosed
WO-2001047919-A1 SUBSTITUTED OXAZOLIDINONES AND THEIR USE IN THE FIELD OF BLOOD COAGULATION BAYER AKTIENGESELLSCHAFT (DE) 2001-07-05 WO disclosed